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GUEST EDITORIAL
Sentinel Lymph Node Biopsy for Thin Melanoma-Con
MICHAEL S. SABEL, MD*
University of Michigan, Ann Arbor, Michigan
When sentinel lymph node biopsy (SLNB) for the regional stag-
ing of melanoma was first introduced, it was recommended for any
patient with a melanoma between 1.0 and 4.0 mm in Breslow thick-
ness. Patients with thin melanomas were not felt to have a sufficient-
ly high risk to warrant the additional cost and morbidity of the
procedure. As experience grew, several retrospective series identified
risk factors beyond Breslow thickness that were associated with an
increased risk of regional metastases, and should therefore prompt
consideration of SLN biopsy for patients with melanomas shy of
1.0 mm (generally considered to be 0.76–0.99 mm). These were
quite varied and included Clark level IV or V, ulceration, mitotic rate
(MR), angiolymphatic invasion, and the age of the patient (younger
patients having a higher rate of SLN metastases than their older
counterparts), with the last three being the most consistent. SLN bi-
opsy is also often recommended for patients with thin melanoma
who have significant regression or a positive deep margin, as the true
Breslow thickness is often unknown.
When the most recent version of the AJCC staging system for
melanoma was released [1], one of the most significant changes was
the classification of stage T1b as any melanoma 1.00 mm with
ulceration or a MR of 1/mm2. Despite the caveat that ‘‘the AJCC
Melanoma Staging Database did not contain sufficient data to assess
risk of occult nodal micrometastases in this population,’’ many sur-
geons have advocated extending the indications for SLNB to include
any T1b melanoma. This would include any melanoma <0.76 mm
with a MR of at least 1/mm2. However, this is not an accurate inter-
pretation of the data. One might assume that the majority of these
patients recur regionally first, then distally, and survival may be im-
pacted because of regional recurrence. However, recent data suggests
that this is not true; T1b status does not impact regional recurrence
but does increase the likelihood of distant recurrence [2]. These data
support the new AJCC staging system for prognostication, but not
for selection for SLNB.
So should SLN biopsy be performed for patients with T1b mela-
noma? As with most debates in medicine, most of the controversy
centers on the semantics. Are there some patients with T1b melano-
mas who require SLN biopsy? Absolutely, this has never been in
debate, as discussed above. So the real controversy centers on two
questions:
1 What is the risk of identifying regional disease in patients with
melanoma <0.76 mm?
2 Among these patients, does a MR of 1/mm2 sufficiently increase
risk to justify the procedure?
Regarding the risk of regional disease for patients with melano-
mas <1.00 mm, most of the data comes from retrospective series
where patients routinely had SLNB for melanoma 1.00 mm (or
>0.75 mm in some series) and selectively had SLNB for thinner
melanomas. Estimated risks for melanomas 0.75 mm are based on
extrapolations from statistical models. However, a careful analysis of
papers advocating SLNB for thin melanomas show most if not all
potential benefit is limited to patients with melanomas between 0.76
and 0.99 mm, the group for whom we currently recommend consid-
eration. Retrospective series consistently show a SLN positivity rate
of less than 2–3% for melanoma <0.75 mm [3]. As these patients
were already specifically selected for SLNB based on adverse
features, this may over-estimate the risk among the entire T1b
population.
Performing SLNB even for intermediate thickness melanoma
remains slightly controversial, as the Multicenter Selective
Lymphadenectomy Trial-1 (MSLT-1) has yet to demonstrate an over-
all survival benefit to the addition of SLNB to wide excision of inter-
mediate-thickness (1.2–3.5 mm) melanoma.[4] This is primarily
because any potential benefit is limited to the node positive popula-
tion (16% in the MSLT-I trial) and subset analysis suggests the bene-
fit is only around 10–15%. With a decreasing likelihood of finding
regional metastases, the absolute benefit of the procedure also
decreases, and the risk-benefit ratio tilts significantly more towards
risk. As the addition of SLNB to wide excision significantly
increases both the costs and the morbidity, it is difficult to justify the
use of SLN biopsy in patients with melanoma 0.75 mm [5–7].
The second question centers on whether a MR of 1/mm2 or great-
er justifies performing SLN biopsy. A cut-off of <1 and 1 mm2
clearly discriminates between patients with a worse outcome, but
does not necessarily identify a group of patients with thin melanoma
who harbor a sufficient risk of regional disease [1,2]. While MR is
associated with the risk of finding a positive SLN, it is best consid-
ered as a continuous variable, and the impact of MR on risk varies
with both age and Breslow thickness [8–10]. The contribution of MR
as an adverse risk factor when selecting patients with thin melanoma
for SLN biopsy must not only be based on the value (as opposed to
simply <1 or 1) but also in the context of increasing age and de-
creasing Breslow thickness. While they are both staged as T1b, the
recommendations for SLN biopsy should be not be the same for a
65-year old patient with a 0.6 mm melanoma and a MR of 2 com-
pared with a 33-year old patient with a 0.6 mm melanoma and a MR
of 12.
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Data from large national databases suggest that SLNB is only
being utilized in a fraction of patients with intermediate-thickness
melanoma, those patients most likely to benefit from the procedure
[11,12]. At this time, our efforts and resources are better spent
addressing the utilization of SLNB among this population. In addi-
tion, we should continue our attempts to identify clinical, molecular,
or proteomic markers associated with a sufficient risk of regional
metastases among patients with melanomas <0.75 mm so as to iden-
tify a subset who should be offered the procedure. Until that time,
the standard recommendations for SLNB (melanoma 1 or 0.76–
0.99 mm with adverse features) should not be extended to include
all T1b patients.
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